Open AccessGingival overgrowth caused by Olmesartan Medoxomil: Observational study
Author(s) -
Letizia Riggio Bevilacqua,
MG Lorenzon,
Giulia Massari,
M Vasselli,
Daniela Angerame,
Marco Maglione,
Di Lenarda R,
Di Lenarda A
Publication year - 2019
Publication title -
journal of medical research
Language(s) - English
Resource type - Journals
ISSN - 2395-7565
DOI - 10.31254/jmr.2019.5504
Subject(s) - olmesartan , medicine , hydrochlorothiazide , angiotensin ii receptor antagonist , pharmacology , candesartan , antagonist , renin–angiotensin system , endocrinology , urology , angiotensin ii , diuretic , essential hypertension , angiotensin receptor , receptor , blood pressure
Objective: Olmesartan Medoxomil is a type 1 receptor antagonist an antagonist of type 1 receptor (AT1) of angiotensin II (A-II) that inhibits numerous actions of A-II in the renin-angiotensin-aldosterone system (RAAS). A-II is a significant and multifunctional peptide involved in the pathophysiology of blood hypertension and for this reason it represents the main target in several classes of drugs used to treat and control arterial hypertension, such as angiotensin converting enzyme inhibitors (ACE-i), angiotensin receptor blockers (ARB) and renin direct inhibitors. The aim of the study is to evaluate whether the two drugs that have as an active principle Olmesartan Medoxomil, with and without the diuretic hydrochlorothiazide, are able to determine gingival overgrowth. Study Design: 108 subjects were examined and divided into three groups: G1, subjects treated with Olmesartan Medoxomil and hydrochlorothiazide (n=60); G2, subjects received only Olmesartan Medoxomil (n=24); G3, control group without pharmacological therapies (n=24). The plaque index (IP) and the gingival overgrowth index (OI) were recorded, considering the vertical and horizontal components. Results: Vertical overgrowth averaged between 0.17 ± 0.15 (G3) and 0.34 ± 0.26 (G2) showing statistically significant differences (p <0.05) compared to the other groups. Horizontal overgrowth ranged from 0.18 ± 0.26 (G3) to 0.49 ± 0.35 (G2) showing statistically significant differences (p <0.05). Conclusions: antihypertensive agents as Olmesartan Medoxomil may result in mild gingival overgrowth in the upper and lower frontal dental elements not related to other etiological factors.